{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:50:11Z","timestamp":1765889411073,"version":"3.38.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from among 51 novel drugs awaiting US Food and Drug Administration approval. New drugs for severe rare diseases, cancers, autoimmune diseases, acute pain, and reversal of anticoagulation are being developed. Additionally, a new cell therapy for treatment of graft-versus-host disease joined the group of novel targeted therapies for various diseases awaiting approval.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Novel therapies for treating rare diseases and cancers continue to strengthen the current drug pipeline.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae352","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:22:55Z","timestamp":1732332175000},"page":"291-296","source":"Crossref","is-referenced-by-count":4,"title":["Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025)"],"prefix":"10.1093","volume":"82","author":[{"given":"Matthew H","family":"Rim","sequence":"first","affiliation":[{"name":"Northwestern Medicine , Chicago, IL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin","family":"Dean","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enela","family":"Aliaj","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Dandino","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Tanriverdi","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"Levitsky","sequence":"additional","affiliation":[{"name":"IPD Analytics , Aventura, FL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"year":"2023","key":"2025030717060747300_CIT0001"},{"key":"2025030717060747300_CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae242","article-title":"Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)","author":"Rim","year":"2024","journal-title":"Am J Health Syst Pharm"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0003"},{"author":"Ascendis Pharma","key":"2025030717060747300_CIT0004"},{"author":"Genentech","key":"2025030717060747300_CIT0005"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0006"},{"author":"Galderma","key":"2025030717060747300_CIT0007"},{"author":"Eli Lilly and Company","key":"2025030717060747300_CIT0008"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0009"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0010"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0011"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0012"},{"author":"Citius Pharma","key":"2025030717060747300_CIT0013"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0014"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0015"},{"author":"US Food and Drug Administration","key":"2025030717060747300_CIT0016"},{"author":"Biospace","key":"2025030717060747300_CIT0017"},{"year":"2024","author":"OncLive","key":"2025030717060747300_CIT0018"},{"year":"2024","author":"Cancer Network","key":"2025030717060747300_CIT0019"},{"year":"2024","author":"Checkpoint Therapeutics","key":"2025030717060747300_CIT0020"},{"year":"2024","author":"Medexus","key":"2025030717060747300_CIT0021"},{"year":"2024","author":"Cancer Network","key":"2025030717060747300_CIT0022"},{"year":"2024","author":"Syndax Pharmaceuticals, Inc","key":"2025030717060747300_CIT0023"},{"year":"2024","author":"Syndax Pharmaceuticals, Inc","key":"2025030717060747300_CIT0024"},{"year":"2024","author":"Targeted Oncology","key":"2025030717060747300_CIT0025"},{"author":"Biospace","key":"2025030717060747300_CIT0026"},{"author":"Pharmaceutical Technology","key":"2025030717060747300_CIT0027"},{"author":"Biospace","key":"2025030717060747300_CIT0028"},{"author":"Fierce Pharma","key":"2025030717060747300_CIT0029"},{"issue":"9","key":"2025030717060747300_CIT0030","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"author":"Johnson & Johnson","key":"2025030717060747300_CIT0031"},{"author":"Drugs.com","key":"2025030717060747300_CIT0032"},{"author":"Vertex Pharmaceuticals","key":"2025030717060747300_CIT0033"},{"author":"Vertex Pharmaceuticals","key":"2025030717060747300_CIT0034"},{"year":"2024","author":"OncLive","key":"2025030717060747300_CIT0035"},{"issue":"16 suppl","key":"2025030717060747300_CIT0036","doi-asserted-by":"publisher","first-page":"abstract 3016","DOI":"10.1200\/JCO.2024.42.16_suppl.3016","article-title":"ReNeu: a pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN)","volume":"42","author":"Moertel","year":"2024","journal-title":"J Clin Oncol."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae352\/60986288\/zxae352.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/6\/291\/60986288\/zxae352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/6\/291\/60986288\/zxae352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:06:13Z","timestamp":1741367173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/6\/291\/7907313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,23]]},"published-print":{"date-parts":[[2025,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae352","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,3,15]]},"published":{"date-parts":[[2024,11,23]]}}}